What Is GLP-1? Benefits, Research & Safety
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
UK summary: Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.
Quick Facts
Overview
GLP-1 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Native GLP-1 not used; GLP-1 agonists are approved medications.
- EU: Multiple GLP-1 receptor agonists approved for diabetes and obesity.
- Notes: The biological understanding of GLP-1 has led to the development of highly successful medications including semaglutide, liraglutide, and others.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Oral 'GLP-1 boosters' raise natural GLP-1 levels and produce weight loss.
- Bitter-melon, berberine, or natural GLP-1 supplements substitute for semaglutide.
- Native GLP-1 peptide is available for injection and works like Ozempic.
07Common internet claims
- Marketed in supplements as 'natural GLP-1' or 'GLP-1 activators'.
- Sold by some online retailers as research-only injectable GLP-1.
- Promoted in wellness blogs as a lifestyle alternative to prescription GLP-1 agonists.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “GLP-1 supplements raise your natural GLP-1 levels” | E | No | High | Native GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated. |
| “GLP-1 is the same as Ozempic” | E | No | High | Ozempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Native GLP-1 is endogenous, with minutes-long half-life; the underlying biology is well characterised.
- Injectable 'native GLP-1' from grey-market sources has unverified identity and sterility.
- Supplement-route 'GLP-1 boosters' have no consistent safety profile because their actual mechanisms vary.
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
Native GLP-1 not used; GLP-1 agonists are approved medications.
14EU legal position
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
15What this page cannot tell you
- Whether any oral 'GLP-1 booster' supplement actually raises GLP-1 in your body.
- Whether injectable native-GLP-1 products contain GLP-1 or a different compound.
- How injectable native GLP-1 would differ pharmacokinetically from licensed analogues (it would be far too short-acting to be useful).
16Last reviewed
17Citation quality score
18Research gaps
- Lifestyle interventions (diet composition, meal timing) that meaningfully modulate endogenous GLP-1 response are studied but effects are small versus pharmacological GLP-1 agonism.
19Safer alternatives / established care pathways
- Licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) via UK prescriber where clinically indicated.
- Lifestyle interventions (Mediterranean-style diet, protein-adequate meals, regular exercise) that support normal incretin response.
- NHS Tier 2 / Tier 3 weight management programmes for structured behaviour change.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
- What lifestyle approaches enhance natural incretin response?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Glucose-dependent insulin secretion (low hypoglycaemia risk)
- 2Improved glycaemic control in type 2 diabetes
- 3Appetite suppression and weight loss
- 4Delayed gastric emptying contributing to satiety
- 5Potential beta cell preservation
- 6Cardiovascular benefits observed with GLP-1 agonists
Claim vs Evidence
How popular claims about GLP-1 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “GLP-1 supplements raise your natural GLP-1 levels” | E | No | High | Native GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated. |
| “GLP-1 is the same as Ozempic” | E | No | High | Ozempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Native GLP-1 is not used therapeutically due to short half-life |
| Frequency | N/A for native GLP-1 |
| Duration | N/A |
| Notes | Native GLP-1 is not practical for therapeutic use. Instead, GLP-1 receptor agonists (semaglutide, liraglutide) or DPP-4 inhibitors are used to achieve GLP-1-like effects. |
Administration Routes
Routes studied in research settings (educational only):
- Native GLP-1 would require continuous infusion (not practical)
- GLP-1 analogues: subcutaneous injection or oral (for semaglutide)
| Half-Life | Stability |
|---|---|
| 1-2 minutes for native GLP-1 (rapidly degraded by DPP-4) | Native GLP-1 is highly unstable; analogues have been engineered for stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Not applicable for native GLP-1 (not used therapeutically)
- See semaglutide and liraglutide entries for GLP-1 agonist side effects
Rare Risks & Concerns
- GLP-1 agonist class effects include pancreatitis risk, gallbladder disease
Contraindications
- See specific GLP-1 agonist entries for contraindications
UK & EU Regulatory Context
🇬🇧 United Kingdom
Native GLP-1 not used; GLP-1 agonists are approved medications.
🇪🇺 European Union
Multiple GLP-1 receptor agonists approved for diabetes and obesity.
Clinical Studies Summary
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
The rest of the authors have no conflicts to declare. The relationships disclosed by the authors did not influence the design, conduct, or interpretation of the data presented in this study.
GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.
GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated. These findings support GLP-1-based therapy as an effective component of clinical obesity management.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.
GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.
This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.
Registered Trials & Regulatory Status
48 of 56 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
Status: Not Yet Recruiting · 80 participants · Mayo Clinic
Conditions: Genetic Predisposition, Type2diabetes
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Status: Not Yet Recruiting · 164 participants · Biophytis
Conditions: Muscle Wasting, Obesity & Overweight, Obesity
Incretin Therapies in Obesity-related HFpEF
Status: Not Yet Recruiting · 50 participants · Columbia University
Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals
Status: Enrolling By Invitation · 14 participants · University of Copenhagen
Conditions: Emesis
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
Status: Recruiting · 20 participants · St. Jude Children's Research Hospital
Conditions: Acute Lymphoblastic Leukemia, Obesity
Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy
Status: Recruiting · 50 participants · University of South Carolina
Conditions: Obesity Type 2 Diabetes Mellitus, Obesity
Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
Status: Recruiting · 150 participants · San Raffaele Telematic University
Conditions: Obesity & Overweight, Taste Alterations, Weight Loss
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Status: Recruiting · 100 participants · Northwestern University
Conditions: Multiple Sclerosis
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
Status: Recruiting · 60 participants · Mayo Clinic
Conditions: PreDiabetes
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Status: Active Not Recruiting · 30 participants · Mayo Clinic
Conditions: Obesity
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Status: Not Yet Recruiting · 60 participants · Taipei Veterans General Hospital, Taiwan
Conditions: Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Status: Recruiting · 420 participants · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions: Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for GLP-1?
Source research-grade GLP-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GLP-1
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
- What lifestyle approaches enhance natural incretin response?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more